Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-6 vs Mecasermin (Increlex)
An educational, source-based comparison of GHRP-6 and Mecasermin (Increlex) — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.
- Severe primary IGF-1 deficiency
- Growth failure with GH gene deletion and neutralizing GH antibodies
- • FDA-approved.
- • Hypoglycemia — must be taken with food.
- • Tonsillar hypertrophy, intracranial hypertension reported.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-6 | GHRP-6 and the ghrelin receptor: cardiometabolic effects | Cardiovascular Research | 2010 | Review of GH-independent cardioprotective signaling observed in animal models. |
| Mecasermin (Increlex) | Mecasermin in severe primary IGFD | JCEM | 2007 | Improved height velocity over multi-year follow-up. |
Side-effect & safety grid
- Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- Not FDA-approved; banned by WADA.
- FDA-approved.
- Hypoglycemia — must be taken with food.
- Tonsillar hypertrophy, intracranial hypertension reported.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-6 vs Mecasermin (Increlex) — Key differences
- Class: GHRP-6 is classified as Growth Hormone Axis, while Mecasermin (Increlex) is IGF-1 · Endocrine.
- Primary research focus: GHRP-6 — endogenous gh pulse stimulation; Mecasermin (Increlex) — severe primary igf-1 deficiency.
- Tag: Growth hormone · Appetite vs FDA-Approved · Endocrine.